Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade ...

US stock markets showed mixed but slightly positive performance on April 9, 2025, with the Nasdaq leading, up 1.25%.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Pfizer may soon play pharmaceutical musical chairs by relocating some of its overseas drug production back to the U.S., responding to the tariff tango initiated by President Trump. Pfizer CEO Albert ...

We recently published a list of 11 Best Innovative Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc.

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President ...

We put performance trends for stocks, sectors, bonds, and funds into perspective, and offer outlooks for the next quarter.

In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.

At present, Healthcare’s dividend yield is 7.3% at 31 cents per share. Over a year, HR stock is up nearly 20%, effectively ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...